What is PellePharm?
PellePharm is a dedicated biotechnology firm focused on pioneering precision medicine approaches for rare dermatological diseases, with a particular emphasis on Gorlin Syndrome and Basal Cell Carcinomas. The company's lead investigational asset is patidegib, a topical treatment designed to mitigate tumor burden in patients. Through strategic collaborations, including partnerships with the Gorlin Syndrome Alliance, PellePharm aims to accelerate research and improve outcomes for individuals affected by these challenging conditions. The absence of current FDA-approved options in this therapeutic area underscores the critical need for PellePharm's innovative work.
How much funding has PellePharm raised?
PellePharm has raised a total of $99.8M across 6 funding rounds:
Private Equity
$1.3M
Private Equity
$4.5M
Private Equity
$719K
Private Equity
$3.2M
Series B
$20M
Unspecified
$70M
Private Equity (2014): $1.3M, investors not publicly disclosed
Private Equity (2015): $4.6M, investors not publicly disclosed
Private Equity (2015): $719K, investors not publicly disclosed
Private Equity (2016): $3.2M, investors not publicly disclosed
Series B (2017): $20M backed by BridgeBio
Unspecified (2018): $70M with participation from LEO Pharma
Key Investors in PellePharm
BridgeBio
BridgeBio is a commercial-stage biopharmaceutical company focused on discovering, creating, and delivering transformative medicines for genetic diseases and cancers. Their expertise lies in developing novel therapies for rare conditions, aligning with PellePharm's mission.
LEO Pharma
LEO Pharma is a multinational Danish pharmaceutical company with a strong specialization in dermatology. Their investment indicates a strategic interest in advancing dermatological treatments, particularly those addressing significant unmet needs.
What's next for PellePharm?
The recent major strategic investment positions PellePharm for accelerated development and potential commercialization of its pipeline. This capital infusion is expected to fuel further clinical trials for patidegib and potentially expand research into other rare dermatological indications. The company's focus on precision medicine and addressing unmet needs in underserved patient populations suggests a trajectory aimed at establishing a significant market presence in specialized dermatology. Future endeavors will likely involve navigating regulatory pathways and forging further strategic alliances to maximize patient access to its therapies.
See full PellePharm company page
